Recent evidence has shown that the EBV oncogene LMP1 is not expressed at high levels 14 early after EBV-infection of primary B cells, despite its being essential for the long-term outgrowth 15 of immortalized lymphoblastoid cell lines (LCLs). In this study, we found that expression of LMP1 16 increased fifty-fold between seven days post infection and the LCL state. Metabolic labeling of 17 nascently transcribed mRNA indicated this was primarily a transcription-mediated event. EBNA2, 18
EBV is a highly successful pathogen that latently infects greater than 90% of adults 28 worldwide and is also causally associated with a number of B-cell malignancies. EBV expresses 29 a set of viral oncoproteins and non-coding RNAs during the latent life cycle with the potential to 30 promote cancer. Critical among these is the viral latent membrane protein, LMP1. Prior work 31 suggests that LMP1 is essential for EBV to immortalize B cells, but our recent work indicates that 32 LMP1 is not produced at high levels during the first few weeks after infection. Here, we show that 33 the transcription of LMP1 can be negatively regulated by a host transcription factor, c-Myc. 34
Ultimately, understanding the regulation of EBV-encoded oncogenes will allow us to better treat 35 cancers that rely on these viral products for survival. 36
INTRODUCTION 37
Epstein-Barr virus (EBV) infection of primary human B cells leads to their immortalization, 38 or growth transformation (1). These immortalized cells, called lymphoblastoid cell lines (LCLs), 39 are latently infected by EBV and express a program, called latency III, consisting of nine viral 40 proteins and many non-coding RNAs. LCLs expressing Latency III genes are a model system for 41 EBV-associated malignancies such as Post-Transplant Lymphoproliferative Disease (PTLD) and 42 Diffuse Large B Cell Lymphoma (DLBCL) (1). Characteristic of Latency III is expression of the 43 essential viral oncogene latent membrane protein 1 (LMP1), which is a constitutively active TNF 44 receptor homologue that induces the host NFB and AP-1 signaling pathways to promote survival 45 (2) (3) (4) (5) . LMP1 is both necessary for EBV immortalization of primary human B cells and sufficient to 46 induce lymphomas when expressed in the murine B cell compartment (6, 7) . The regions of the 47 LMP1 cytoplasmic tail that engage TNFR associated factors (TRAFs) and TNFR associated death 48 domain (TRADD) responsible for NFB activation are coincident with the regions required for 49 9) . LCLs are functionally addicted to the NFB signaling 50 induced by LMP1 as inhibition of this pathway results in apoptosis (3). 51
Studies of LMP1 transcriptional regulation have defined cis-acting elements and trans-52 acting factors important in controlling its expression. In epithelial cells, LMP1 expression is driven 53 by a unique promoter found within the viral terminal repeats (10, 11) . However, transcription of 54 LMP1 in Latency III expressing B cells is initiated at a bi-directional LMP1/LMP2B promoter (12) . 55
The critical activator of this Latency III promoter is Epstein-Barr Nuclear Antigen 2 (EBNA2), which 56 binds to a so-called EBNA2-response element (E2RE) through the host factors RBP-J and PU.1 57 (13, 14) . Other viral factors, such as EBNA3C, have also been shown to aid in the transcription 58 of LMP1 (15, 16) . Additionally, a number of host factors have been shown to fine-tune LMP1 59 transcription, including ATF4 (17, 18), IRF7 (19), and NFB subunits themselves (20, 21) . In fact, 60 host factors often lead to auto-regulatory feedback loops that maintain the levels of LMP1 61 expression, whether it is NFB in B cells (20) or STAT signaling on the terminal repeat promoter 62 in epithelial cells (22) . Furthermore, the epigenetic state of the LMP1 promoter plays a key role in 63 transcription. Changes in cell type and latency state alter the prevalence of active and repressive 64 histone marks on the LMP1 promoter as well as CpG DNA methylation (23). In addition, viral 65 chromatin architecture and enhancer looping mediated by host factors such as CTCF and Rad21 66 play a direct role in the full activation of LMP1 (24). 67 LMP1 mRNA is also post-transcriptionally regulated to control protein output. While LMP1 68 is one of the most abundant viral transcripts detected in latently infected cells, it is transcribed at 69 a much lower rate implying a certain level of mRNA stability (25). This stability can be 70 counteracted by micro-RNA (miRNA) targeting of the long LMP1 3' untranslated region. LMP1 71 can be targeted by both EBV-encoded viral miRNAs such as miR-BART1-5p, miR-BART16-3p, 72 and miR-BART17-5p (26) as well as a number of host miRNAs (27) . Of these host miRNAs, 73 inhibiting the c-Myc regulated miR17~92 miRNA cluster led to an upregulation of LMP1 protein 74 levels and slowed cell growth (27) . This slowed growth could be explained in part by the known 75 ability of overexpressed LMP1 to be cytostatic (28) (29) (30) . 76
The cellular oncogene c-Myc is overexpressed in a wide variety of cancers, including EBV-77 associated Burkitt lymphoma where c-Myc is expressed at high levels due to a characteristic 78 chromosomal 8:14 translocation. Additionally, EBV induces c-Myc expression upon infection of B 79 cells by utilizing EBNA2 to co-opt native super-enhancer architecture upstream of c-Myc (31). 80
Upon de novo infection, c-Myc levels peak within the first week after infection, then wane, but 81 remain elevated throughout LCL outgrowth where c-Myc is crucial for the maintenance of the LCL 82 phenotype (32, 33) . This conflicts with the NFB addiction observed in LCLs, as the c-Myc and 83 NFB signaling pathways have been shown to be directly incompatible (34). 84
We have previously shown that, despite being detectable early after infection of primary 85 B cells, LMP1 does not reach LCL levels of expression until greater than two weeks post infection 86 (35). These EBV-infected cells express EBNA2, proliferate, and show no signs of apoptosis even 87 when NFB is inhibited during the first weeks of infection (35, 36) . Furthermore, the exact role of 88 LMP1 in the EBV life cycle has been called into question by recent work showing that LMP1 is 89 dispensable for tumor formation in a humanized mouse model (37, 38) . In this work, we address 90 the question of how LMP1 is delayed in expression from early to late times after primary B-cell 91 infection. We investigate the nature of the mRNA change and the role of cellular factors in 92 temporal regulation of LMP1 expression. 93 94 RESULTS 95 LMP1 transcription is robustly increased from early to late times after primary B cell 96 infection. LMP1 mRNA and protein levels and, consequently, NFB targets are significantly lower 97 during the first two weeks following EBV infection of primary B cells relative to that found in 98 immortalized lymphoblastoid cell lines (LCLs) (35) . Prior studies indicate that the LMP1 mRNA is 99 the most abundant latency transcript in LCLs despite being poorly transcribed (25). Therefore, to 100 determine the mechanism for low LMP1 mRNA levels at early times after infection, we assayed 101 the relative transcription rate and half-life using a 4-thiouridine (4sU) metabolic labeling approach 102 ( Fig. 1A and (39)). This was performed by using Fluorescence Activated Cell Sorting (FACS) to 103 generate a pure population of proliferating (Celltrace Violet lo ) EBV-infected B cells six days after 104 primary human Peripheral Blood Mononuclear Cell (PBMC) infection and allowing the cells to rest 105 overnight. Twenty-four hours later (Day 7 post infection), cells were pulsed with 4sU for exactly 106 one hour before total RNA was harvested. The process was repeated for LCLs that grew out from 107 matched PBMC donors five weeks post infection. As previously observed, the total LMP1 mRNA 108 level increased ~50-fold from day 7 post infection through LCL outgrowth ( Fig. 1B) . Comparing 109 the ratio of 4sU labeled nascent RNA and unlabeled decaying RNA (39), we found that the half-110 life of the LMP1 mRNA increased two-fold between early and late times after infection from ~2 111 hours at 7 days post infection to ~4 hours in LCLs (Fig. 1C) . Over the same time frame the relative 112 transcription rate of LMP1 mRNA increased nearly 25-fold ( Fig. 1D) . We also queried the EBNA2-113 specific mRNA as well as Cp-derived EBNA transcripts and found only modest differences in their 114 overall expression, transcription rate, or stability through B cell outgrowth ( Fig. 1B-D) . 115
The LMP1 locus is occupied by EBNA2 and CTCF similarly early and late after infection; 116 however lower levels of activated histones are detected early. In B cells, the transcription of 117 LMP1 is regulated by EBNA2 (40). Prior work indicates that EBNA2-regulated genes, including c-118
Myc and CD23, are induced to higher levels at day 7 post infection than in LCLs suggesting that 119 EBNA2 activity is not broadly suppressed during early infection (32). However, it remained a 120 possibility that LMP1 expression was low during early infection because of poor EBNA2 121 recruitment to the bi-directional LMP1/2B promoter. To address this, we performed Chromatin 122
Immuno-precipitation (ChIP) for EBNA2 at day 7 post infection and in LCLs. LMP1 and LMP2 are 123 transcribed from a complex and overlapping region of the EBV episome near the terminal repeats 124 (TR), diagrammed in Fig. 2A . We found that EBNA2 was recruited comparably to the LMP1 125 promoter and the viral C promoter both early after infection and in LCLs (Fig. 2B) . A region in the 126 gene body of EBNA3C distal to both the LMP1p and the Cp was used as a negative control ( Fig.  127   2B) . Similarly, EBNA2 was recruited to the two major c-Myc upstream enhancer loci (31) as well 128 as the CD23 promoter comparably at 7 days post infection as in LCLs (Fig. 2C) . Despite the lack 129 of change in EBNA2 occupancy at early and late times post infection, the activating histone mark 130 H3K9 Acetyl was enriched at the LMP1p in LCLs, correlating with the observed increased level 131 of transcription ( Fig. 2D) . A recent publication has implicated the chromatin architecture mediated 132 by CTCF at a single CTCF site downstream of LMP1 (here called the CTCF-Response Element) 133 to be important for H3K9 Acetylation and transcription at the LMP1 promoter (24). We assayed 134 for CTCF-occupancy at both this CTCF-RE as well as the EBV enhancer found in the EBER/OriP 135 region of the genome and found that CTCF occupancy did not change between day 7 post 136 infection cells and LCLs ( Fig. 2E) . 137 c-Myc suppresses LMP1 transcription. Despite EBNA2 recruitment to the LMP1 promoter, 138 reduced H3K9 acetylation suggested poor LMP1 transcription. Early after infection when LMP1 139 expression is lowest, c-Myc is strongly activated by EBNA2, and during the time frame that LMP1 140 expression increases the expression of c-Myc and its targets are subsequently attenuated (32). 141
Given this correlation, we sought to test the role of c-Myc in the regulation of LMP1 expression. 142
We first assayed LMP1 transcription using 4sU labeling in EBV-infected Burkitt lymphoma (BL) 143 cell lines that express very high levels of c-Myc relative to LCLs. We found that LMP1 mRNA and 144 protein levels were higher in LCLs than in EBV-infected BL41 cells ( Fig. 3A-B) . Consistent with 145 our hypothesis, the transcription of LMP1 was significantly lower in EBV-infected BL41 cells 146 relative to LCLs (Fig. 3C) . 147
To directly assess the effect of c-Myc on LMP1 transcription in an LCL, we used the P493-148 6 model of c-Myc and EBNA2 regulation (41, 42). In this system, EBNA2 (encoded endogenously 149 from the viral genome) is controlled post-translationally by Estrogen (-Estradiol) due to its fusion 150 to a modified estrogen receptor, and heterologous c-Myc expression is provided in trans and 151 controlled transcriptionally through a tetracycline (tet-off) system. We verified that induction of 152 EBNA2 and inactivation of c-Myc (Estrogen+, Tetracycline+) led to an LCL-like phenotype with 153 high levels of LMP1 transcription (Fig. 4A) . However, when removing EBNA2 activity (Estrogen-154 , Tetracycline-) or inducing EBNA2 in the presence of high levels of c-Myc (Estrogen+, 155 Tetracycline-), we observed blunted endogenous LMP1 transcription relative to that induced in 156 the presence of low levels of c-Myc (Fig. 4A) . These changes in transcription correlated with the 157 levels of total LMP1 mRNA and protein ( Fig. 4B-C) , while EBNA2-ER transcription from the 158 endogenous Cp was not affected by c-Myc overexpression (Fig. 4B) . This controlled experiment 159 indicated that c-Myc overexpression is sufficient to suppress LMP1 transcription in an LCL and 160
suggested that c-Myc may be critical for suppression of LMP1 transcription early after primary B-161 cell infection as well. Therefore, we used two independent BET inhibitors, JQ1 and OTX015, to suppress c-Myc and 168 assay LMP1 transcription in EBV-infected cells. First, we treated LCLs with the BET inhibitors and 169 found that c-Myc mRNA levels decreased and LMP1 mRNA levels increased in a dose-dependent 170 manner ( Fig. 5A-B) . We next treated EBV-infected PBMCs 7 days post infection with BET 171 inhibitors. Consistently, we observed a dose-dependent decrease in c-Myc mRNA and increase 172 in LMP1 mRNA following both JQ1 and OTX015 treatment ( Fig. 5C-D) . Therefore, c-Myc activity 173 negatively correlates with LMP1 expression both early and late after infection. 174
DISCUSSION 175
In this study, we determined that transcription of the EBV major latent oncoprotein, LMP1, 176 is suppressed by c-Myc early after primary B cell infection. Transcription of LMP1 increased 177 twenty-five-fold from day 7 to LCL, while the mRNA half-life increased two-fold, leading to an 178 overall fifty-fold increase in LMP1 expression. This change correlated with an approximate two-179 fold increase in the activating histone mark, H3K9Ac, at the LMP1 promoter, but the occupancy 180 of the major LMP1 trans-activator EBNA2, as well as CTCF-binding to the CTCF-RE, did not The small but significant change in LMP1 half-life could be explained as a post-188 transcriptional effect mediated by miRNAs that are known to target the LMP1 3'UTR. Previous 189 work has shown that the miR17~92 family of c-Myc-induced miRNAs target LMP1 and removal 190 of this miRNA family increased LMP1 protein production (27). Furthermore, our group has shown 191 that miR17~92 are expressed at the highest levels early after infection when LMP1 mRNA and 192 mRNA half-life is lowest (45). This low level "fine-tuning" of LMP1 expression might be critical in 193 the immortalized state when high levels of LMP1 can lead to cytostatic effects on cell growth (28, 194 30). 195 While the LMP1 promoter has been extensively studied in the immortalized LCL, no one 196 has previously characterized promoter occupancy early after infection. We have shown that early 197 after infection EBNA2 is recruited normally to its response element in the LMP1 promoter as well 
MATERIALS AND METHODS 233

Cell lines, culture conditions, and viruses 234
Buffy coats were obtained from normal human donors through the Gulf Coast Regional 235 Blood Center (Houston, TX) and peripheral blood mononuclear cells (PBMCs) were isolated by 236
Ficoll Histopaque-1077 gradient (Sigma, H8889). B95-8 strain of Epstein-Barr virus was produced 237 from the B95-8 Z-HT cell line as previously described (52). Virus infections were performed in 238 bulk by adding 50 µL of filtered B95-8 supernatant to 1x10 6 PBMCs. 239
Cell lines were cultured in RPMI 1640 media supplemented with 10-15% heat inactivated 240 fetal bovine serum (Corning), 2 mM L-Glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin 241 (Invitrogen), and 0.5 µg/mL Cyclosporine A (Sigma). P493-6 cells (a kind gift of Dr. Georg 242 Bornkamm, Helmholtz Zentrum München) were cultured with 10% tetracycline-free FBS (Hyclone 243 SH30070), 1 µM -Estradiol, and 1 µg/mL Tetracycline. All cells were cultured at 37°C in a 244 humidified incubator at 5% CO 2. 245
Flow cytometry and sorting 246
To track proliferation, cells were stained with CellTrace Violet (Invitrogen, C34557), a 247 fluorescent proliferation-tracking dye. Cells were first washed in FACS buffer (5% FBS in PBS), 248 stained with the appropriate antibody for 30min-1hr at 4°C in the dark, and then washed again 249 before being analyzed on a BD FACS Canto II. following the manufacturer's protocol (Life Technologies). 4sU-labelled nascent RNA was then 259 biotinylated using a highly efficient crosslinking reaction using EZ-Link Biotin-HPDP (Pierce) 260 dissolved in DMSO at a concentration of 1 mg/mL or MTSEA Biotin-XX (Biotium Cat# 90066) at 261 20 ng/uL dissolved in DMSO, and labeled RNA was separated from the total population using 262 streptavidin MyOne C1 Dynabeads (Invitrogen) as previously described (39). Subsequently, three 263 populations of RNA were reverse transcribed into cDNA using the High Capacity cDNA kit 264 (Applied Biosystems): total RNA (T), unlabeled RNA (U), and nascent RNA (N). Quantitative real-265 time PCR was then performed on these three populations to discover total RNA abundance, 266 relative transcription rates, and mRNA half-life as previously described (53 
Western blot 301
Cells were pelleted and washed in PBS, and then lysed in 0.1% Triton-containing buffer 302 with Complete protease inhibitors. All protein lysates were run on NuPage 4-12% gradient gels 303 (LifeTechnology) and transferred to PVDF membrane (GE Healthcare). Membranes were blocked 304 in 5% milk in TBST and stained with primary antibody overnight at +4°C, followed by a wash and 305 staining with secondary HRP-conjugated antibody for 1 hour at room temperature. Antibodies 306 include LMP1 (S12; gift from Elliot Kieff, Harvard Medical School), c-Myc (Santa Cruz 307 Biotechnology, SC-764), and GAPDH (BioChain Institute, #Y3322). 308
BRD4 Inhibition 309
(+)-JQ1 and OTX015 were purchased from Selleckchem (cat. #S7110 and #S7360, respectively). 310
For LCLs: 311
LCLs were seeded at 3*10^5/mL in the presence of either 0.1% DMSO, 100 or 500 nM JQ1 or 312 100 or 500 nM OTX015 for 24 hours. After 24 hours total mRNA was harvested using the Qiagen 313
RNeasy mini kit (ref #74104) according to manufacturer's instructions. 1 microgram of harvest 314 mRNA was reverse transcribed into cDNA using Applied Biosystems High-Capacity cDNA 315 reverse transcription kit (cat #4368814) according to manufacturer's instructions. analysis was performed using SYBR Green detection based system (Quanta Bio cat #95072-317 05K) with 5 ng of cDNA used per reaction using an Applied Biosystems StepOne Plus Real Time 318 PCR System. All values were normalized to the endogenous loading control SETDB1. Relative 319 expression values were calculated using the CT method. 320
For PBMCs: 321
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from whole blood, infected with EBV 322 B95-8 and seeded at 1*10^6/mL. Seven days post infection the cells were treated with either 323 0.1% DMSO, 100 or 500 nM JQ1 or 100 or 500 nM OTX015. After 24 hours, total mRNA was 324 harvested as previously described. 1 g of total RNA was reverse transcribed into cDNA as 325 previously described. RT-qPCR analysis was conducted as previously described. were isolated from whole blood and infected with EBV. On day 7, they were treated with the 385 Each bar is representative of at least 3 independent donors. Error bars represent SEM. * denotes 581 p<0.05, ** denotes p<0.01 and *** denotes p<0.001 by one-tailed pairwise student's t-test. 582 583
